Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Development of carboplatin].

S Tsukagoshi1

  • 1Cancer Chemotherapy Center, Cancer Institute.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|September 1, 1990
PubMed
Summary

Carboplatin (CBDCA) demonstrates efficacy comparable to cisplatin for various cancers. CBDCA exhibits significantly reduced toxicity, making it a valuable option in chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

VALIDATION OF MONTE CARLO DOSE CALCULATION FOR PAEDIATRIC CT EXAMINATIONS USING TUBE CURRENT MODULATION BASED ON IN-PHANTOM DOSIMETRY.

Radiation protection dosimetry·2018
Same author

Buruli ulcer in a nine-month-old boy.

Annals of the Royal College of Surgeons of England·2012
Same author

[Comparison of management of advanced cancer in various organs].

Gan to kagaku ryoho. Cancer & chemotherapy·2001
Same author

[Results of gemcitabine hydrochloride in the treatment for pancreatic cancer].

Gan to kagaku ryoho. Cancer & chemotherapy·2001
Same author

[Molecular specificity of nafamostat mesilate (FUT), a drug used for the treatments of DIC and acute pancreatitis and as an anticoagulant--the pharmacodynamics and pharmacological action].

Gan to kagaku ryoho. Cancer & chemotherapy·2001
Same author

[Clinical effects of a 3-month formulation LH-RH agonist (Zoladex LA 10.8 mg depot) in patients with prostate cancer].

Hinyokika kiyo. Acta urologica Japonica·2001

Area of Science:

  • Oncology
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Carboplatin (CBDCA) is a platinum-based chemotherapy agent, a derivative of cisplatin (CDDP).
  • Preclinical studies indicated comparable anti-tumor effectiveness between CBDCA and CDDP against murine tumors.
  • CBDCA features a cyclobutanedicarboxylic acid group, differentiating its chemical structure from CDDP.

Purpose of the Study:

  • To evaluate the efficacy and toxicity profile of carboplatin (CBDCA) in preclinical and clinical settings.
  • To compare carboplatin's pharmacokinetic properties and side effects with those of cisplatin (CDDP).
  • To establish carboplatin's potential role in cancer chemotherapy.

Main Methods:

  • Comparative analysis of anti-tumor activity in murine models.
  • Pharmacokinetic studies measuring platinum concentration in blood over time.
  • Assessment of urinary excretion rates post-administration.
  • Clinical trial evaluations of efficacy and toxicity in cancer patients.

Main Results:

  • Carboplatin showed comparable anti-tumor efficacy to cisplatin in preclinical studies.
  • Higher concentrations of free platinum from carboplatin remained in circulation for longer durations compared to cisplatin.
  • Carboplatin exhibited rapid urinary excretion.
  • Clinical trials reported significant responses in various cancers, including head and neck, lung, ovarian, and testicular tumors.
  • Carboplatin demonstrated substantially lower renal toxicity, nausea, vomiting, and neurotoxicity than cisplatin.
  • Myelosuppression was identified as the dose-limiting factor in Phase I studies.

Conclusions:

  • Carboplatin possesses anti-tumor efficacy similar to cisplatin.
  • Carboplatin offers a significantly improved safety profile with reduced toxicity compared to cisplatin.
  • Carboplatin is a promising and useful agent for contemporary cancer chemotherapy.

Related Experiment Videos